Dosing & Uses
Dosage Forms & Strengths
intravitreal injectable solution
- 6mg/mL (0.05mL [0.3mg/vial])
- 10mg/mL (0.05mL [0.5mg/vial])
Neovascular (Wet) Age-related Macular Degeneration
0.5 mg intravitreal qMonth
May give q3month after 3 or 4 monthly injections (if continued monthly dosing not feasible) but is less effective than once monthly dosing
Indicated for macular edema following retinal vein occlusion
0.5 mg intravitreal injection qMonth x6 months
Diabetic Macular Edema
0.3 mg intravitreally qMonth
Diabetic Retinopathy with DME
Indicated for treatment of diabetic retinopathy in patients with diabetic macular edema (DME)
0.3 mg intravitreally qMonth
Does not apply
Serious - Use Alternative
Significant - Monitor Closely
Conjunctival hemorrhage (43-77%)
Eye pain (17-37%)
Vitreous floaters (3-32%)
Incr IOP (8-24%)
Vitreous detachment (7-22%)
Eye irritation (4-19%)
Intraocular inflammation (5-18%)
Upper resp tract infection (2-15%)
Retinal disorder (13%)
Retinal degeneration (1-11%)
Conjunctival hyperemia (9%)
Posterior capsule opacification (8%)
Injection site hemorrhage (5%)
Vitreous hemorrhage (4%)
Risk of endophthalmitis or retinal detachment with intravitreous injections
Possibility of IOP increase within 60 min of intravitreal injection
Potential for adverse thromboembolic events (eg, nonfatal stroke, nonfatal MI, vascular death)
Temporary visual disturbances may occur
The incidence of fatal events reported to be higher in diabetic macular edema
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Unknown if distributed in milk; use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Humanized monoclonal antibody to VEGF-A, inhibits VEGF-A-induced ocular neovascularization
Half-Life: 9 days (vitreous)
Peak PlasmaTime: 1 day
Peak Plasma Concentration: 0.3-2.36 ng/mL
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs